COLL
Collegium Pharmaceutical, Inc.
Price Chart
Latest Quote
$33.57
-0.11 (-0.33%)
Current Price
| Previous Close | $33.68 |
| Open | $34.09 |
| Day High | $34.27 |
| Day Low | $33.01 |
| Volume | 124,106 |
Stock Information
| Shares Outstanding | 32.43M |
| Total Debt | $929.69M |
| Cash Equivalents | $421.75M |
| Revenue | $796.33M |
| Net Income | $74.95M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | $1.09B |
| P/E Ratio | 16.28 |
| EPS (TTM) | $2.06 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.60B |
| Sales | $796.33M |
| Income | $74.95M |
| Book/sh | $9.64 |
| Cash/sh | $13.00 |
| Employees | 423 |
Financial Ratios
| Quick Ratio | 1.50 |
| Current Ratio | 1.71 |
| Debt/Eq | 297.57 |
| EPS Growth TTM | 499.80% |
Returns & Margins
| ROA | 7.60% |
| ROE | 27.41% |
| Gross Margin | 89.17% |
| Operating Margin | 15.96% |
| Profit Margin | 9.41% |
Ownership
| Insider Ownership | 1.16% |
| Institutional Ownership | 127.86% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 4.41 |
| P/S | 1.37 |
| P/B | 3.48 |
Analyst Data
| Recommendation | none |
| Target Price | $54.33 |
Technical Indicators
| SMA20 | $33.49 |
| SMA50 | $34.14 |
| SMA200 | $39.30 |
| RSI | 49.67 |
| ATR | 1.4038 |
| Shares Float | 32.05M |
| Short Float | 20.88% |
| Short Ratio | 12.97 |
| Volatility | 0.75 |
| Rel Volume | 1.66 |
Performance History
| Week | -2.33% |
| Month | -0.24% |
| Quarter | -7.60% |
| 6 Months | -31.14% |
| YTD | -26.33% |
| Year | +13.93% |
| 3 Years | +47.88% |
| 5 Years | +43.52% |
| 10 Years | +136.20% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $33.54 | 631,900 |
| 2026-06-17 | $33.68 | 413,600 |
| 2026-06-16 | $34.65 | 181,700 |
| 2026-06-15 | $34.19 | 408,100 |
| 2026-06-12 | $34.64 | 278,500 |
| 2026-06-11 | $34.34 | 461,400 |
| 2026-06-10 | $34.80 | 375,000 |
| 2026-06-09 | $34.40 | 258,000 |
| 2026-06-08 | $33.27 | 422,400 |
| 2026-06-05 | $33.38 | 333,400 |
| 2026-06-04 | $32.69 | 350,100 |
| 2026-06-03 | $31.06 | 474,300 |
| 2026-06-02 | $30.48 | 668,700 |
| 2026-06-01 | $31.78 | 512,000 |
| 2026-05-29 | $33.61 | 490,000 |
| 2026-05-28 | $33.37 | 304,700 |
| 2026-05-27 | $33.68 | 377,700 |
| 2026-05-26 | $33.78 | 283,700 |
| 2026-05-22 | $34.07 | 163,800 |
| 2026-05-21 | $34.42 | 206,500 |
| 2026-05-20 | $34.22 | 322,900 |
| 2026-05-19 | $33.62 | 314,400 |
About Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. Collegium Pharmaceutical, Inc. was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. The company was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
đ° Latest News
3 of Wall Streetâs Favorite Stocks We Approach with Caution
StockStory âĸ 2026-06-19T13:48:58Z
2 Reasons to Sell COLL and 1 Stock to Buy Instead
StockStory âĸ 2026-06-03T17:27:33Z
Assessing Collegium Pharmaceutical (COLL) Valuation After Recent Share Price Weakness
Simply Wall St. âĸ 2026-06-02T01:09:07Z
Why Collegium Pharmaceutical Inc. (COLL) Stock Is Gaining Attention for Its ADHD Portfolio
Insider Monkey âĸ 2026-05-27T21:16:23Z
3 Growth Stocks Weâre Skeptical Of
StockStory âĸ 2026-05-26T11:23:49Z
Collegium Pharmaceuticalâs Q1 Earnings Call: Our Top 5 Analyst Questions
StockStory âĸ 2026-05-18T14:44:55Z
Thermo Fisher, Dentsply Sirona, Collegium Pharmaceutical, and Halozyme Therapeutics Stocks Trade Down, What You Need To Know
StockStory âĸ 2026-05-17T09:40:55Z
Collegium Pharmaceutical's (NASDAQ:COLL) Solid Earnings Are Supported By Other Strong Factors
Simply Wall St. âĸ 2026-05-14T11:11:57Z
1 Healthcare Stock with Competitive Advantages and 2 We Brush Off
StockStory âĸ 2026-05-13T20:44:55Z
COLL Q1 Deep Dive: ADHD Portfolio Expansion and Pain Segment Stability Drive Results
StockStory âĸ 2026-05-11T20:04:55Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $317,310,000 | $254,105,000 | $240,598,000 | $254,445,000 |
| Cost Of Revenue | $317,310,000 | $254,105,000 | $240,598,000 | $254,445,000 |
| Total Revenue | $780,567,000 | $631,449,000 | $566,767,000 | $463,933,000 |
| Operating Revenue | $780,567,000 | $631,449,000 | $566,767,000 | $463,933,000 |
| Expenses | ||||
| Interest Expense | $82,312,000 | $73,974,000 | $83,339,000 | $63,213,000 |
| Total Expenses | $602,113,000 | $464,468,000 | $399,806,000 | $430,614,000 |
| Other Income Expense | $-14,812,000 | $-8,415,000 | $-23,504,000 | - |
| Net Non Operating Interest Income Expense | $-71,023,000 | $-59,998,000 | $-67,724,000 | $-62,166,000 |
| Interest Expense Non Operating | $82,312,000 | $73,974,000 | $83,339,000 | $63,213,000 |
| Operating Expense | $284,803,000 | $210,363,000 | $159,208,000 | $176,169,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $62,870,000 | $69,190,000 | $48,155,000 | $-25,002,000 |
| Net Interest Income | $-71,023,000 | $-59,998,000 | $-67,724,000 | $-62,166,000 |
| Interest Income | $11,289,000 | $13,976,000 | $15,615,000 | $1,047,000 |
| Normalized Income | $72,927,348 | $75,097,330 | $63,103,544 | $-25,002,000 |
| Net Income From Continuing And Discontinued Operation | $62,870,000 | $69,190,000 | $48,155,000 | $-25,002,000 |
| Total Operating Income As Reported | $179,636,000 | $169,895,000 | $166,961,000 | $33,319,000 |
| Average Dilution Earnings | $6,007,000 | $5,863,000 | $5,889,000 | $0 |
| Net Income Common Stockholders | $62,870,000 | $69,190,000 | $48,155,000 | $-25,002,000 |
| Net Income | $62,870,000 | $69,190,000 | $48,155,000 | $-25,002,000 |
| Net Income Including Noncontrolling Interests | $62,870,000 | $69,190,000 | $48,155,000 | $-25,002,000 |
| Net Income Continuous Operations | $62,870,000 | $69,190,000 | $48,155,000 | $-25,002,000 |
| Pretax Income | $92,619,000 | $98,568,000 | $75,733,000 | $-28,847,000 |
| Special Income Charges | $-14,812,000 | $-8,415,000 | $-23,504,000 | $0 |
| Interest Income Non Operating | $11,289,000 | $13,976,000 | $15,615,000 | $1,047,000 |
| Operating Income | $178,454,000 | $166,981,000 | $166,961,000 | $33,319,000 |
| Gross Profit | $463,257,000 | $377,344,000 | $326,169,000 | $209,488,000 |
| Per Share | ||||
| Diluted EPS | $1.73 | $1.86 | $1.29 | $-0.74 |
| Basic EPS | $1.98 | $2.14 | $1.43 | $-0.74 |
| Other | ||||
| Tax Effect Of Unusual Items | $-4,754,652 | $-2,507,670 | $-8,555,456 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $415,817,000 | $350,117,000 | $331,832,000 | $173,305,000 |
| Total Unusual Items | $-14,812,000 | $-8,415,000 | $-23,504,000 | $0 |
| Total Unusual Items Excluding Goodwill | $-14,812,000 | $-8,415,000 | $-23,504,000 | $0 |
| Reconciled Depreciation | $226,074,000 | $169,160,000 | $149,256,000 | $138,939,000 |
| EBITDA (Bullshit earnings) | $401,005,000 | $341,702,000 | $308,328,000 | $173,305,000 |
| EBIT | $174,931,000 | $172,542,000 | $159,072,000 | $34,366,000 |
| Diluted Average Shares | $39,701,693 | $40,424,180 | $41,788,125 | $33,829,495 |
| Basic Average Shares | $31,706,429 | $32,273,850 | $33,741,213 | $33,829,495 |
| Diluted NI Availto Com Stockholders | $68,877,000 | $75,053,000 | $54,044,000 | $-25,002,000 |
| Tax Provision | $29,749,000 | $29,378,000 | $27,578,000 | $-3,845,000 |
| Other Special Charges | $15,994,000 | $11,329,000 | $23,504,000 | - |
| Restructuring And Mergern Acquisition | $-1,182,000 | $-2,914,000 | $0 | $0 |
| Selling General And Administration | $284,803,000 | $210,363,000 | $159,208,000 | $172,186,000 |
| Research And Development | - | $0 | $0 | $3,983,000 |
Fetched: 2026-06-18
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-513,760,000 | $-824,893,000 | $-360,134,000 | $-506,321,000 |
| Total Assets | $1,656,834,000 | $1,663,591,000 | $1,143,308,000 | $1,174,131,000 |
| Total Non Current Assets | $965,423,000 | $1,181,334,000 | $605,708,000 | $754,142,000 |
| Other Non Current Assets | $21,249,000 | $9,415,000 | $1,872,000 | $2,647,000 |
| Non Current Deferred Assets | $112,539,000 | $98,033,000 | $26,259,000 | $23,950,000 |
| Non Current Deferred Taxes Assets | $112,539,000 | $98,033,000 | $26,259,000 | $23,950,000 |
| Goodwill And Other Intangible Assets | $815,435,000 | $1,053,735,000 | $555,565,000 | $701,163,000 |
| Other Intangible Assets | $669,510,000 | $891,402,000 | $421,708,000 | $567,468,000 |
| Current Assets | $691,411,000 | $482,257,000 | $537,600,000 | $419,989,000 |
| Other Current Assets | $3,239,000 | $2,742,000 | $93,000 | $57,000 |
| Restricted Cash | $19,850,000 | $25,000,000 | $0 | - |
| Prepaid Assets | $29,403,000 | $27,652,000 | $15,102,000 | $16,624,000 |
| Inventory | $40,912,000 | $35,560,000 | $32,332,000 | $46,501,000 |
| Receivables | $211,328,000 | $228,540,000 | $179,525,000 | $183,119,000 |
| Accounts Receivable | $211,328,000 | $228,540,000 | $179,525,000 | $183,119,000 |
| Cash Cash Equivalents And Short Term Investments | $386,679,000 | $162,763,000 | $310,548,000 | $173,688,000 |
| Cash And Cash Equivalents | $231,252,000 | $70,565,000 | $238,947,000 | $173,688,000 |
| Debt | ||||
| Net Debt | $578,073,000 | $781,923,000 | $428,224,000 | $527,263,000 |
| Total Debt | $814,864,000 | $859,298,000 | $674,283,000 | $709,175,000 |
| Long Term Debt And Capital Lease Obligation | $784,457,000 | $793,444,000 | $489,962,000 | $545,563,000 |
| Long Term Debt | $780,325,000 | $787,905,000 | $483,838,000 | $538,451,000 |
| Current Debt And Capital Lease Obligation | $30,407,000 | $65,854,000 | $184,321,000 | $163,612,000 |
| Current Debt | $29,000,000 | $64,583,000 | $183,333,000 | $162,500,000 |
| Other Current Borrowings | $29,000,000 | $64,583,000 | $183,333,000 | $162,500,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $1,355,159,000 | $1,434,749,000 | $947,877,000 | $979,289,000 |
| Total Non Current Liabilities Net Minority Interest | $915,131,000 | $925,239,000 | $489,962,000 | $545,563,000 |
| Non Current Deferred Liabilities | $130,674,000 | $130,613,000 | $0 | - |
| Current Liabilities | $440,028,000 | $509,510,000 | $457,915,000 | $433,726,000 |
| Other Current Liabilities | $2,435,000 | $3,044,000 | - | - |
| Current Deferred Liabilities | $667,000 | $0 | - | - |
| Payables And Accrued Expenses | $402,805,000 | $436,048,000 | $272,219,000 | $268,607,000 |
| Interest Payable | $12,023,000 | $6,146,000 | $2,853,000 | $1,410,000 |
| Payables | $39,253,000 | $48,075,000 | $15,841,000 | $7,846,000 |
| Other Payable | $17,565,000 | $28,956,000 | - | - |
| Total Tax Payable | $11,029,000 | $15,185,000 | $7,149,000 | $4,352,000 |
| Income Tax Payable | $3,297,000 | $8,525,000 | $2,136,000 | $0 |
| Accounts Payable | $10,659,000 | $3,934,000 | $8,692,000 | $3,494,000 |
| Other Non Current Liabilities | - | $1,182,000 | - | - |
| Equity | ||||
| Common Stock Equity | $301,675,000 | $228,842,000 | $195,431,000 | $194,842,000 |
| Total Equity Gross Minority Interest | $301,675,000 | $228,842,000 | $195,431,000 | $194,842,000 |
| Stockholders Equity | $301,675,000 | $228,842,000 | $195,431,000 | $194,842,000 |
| Gains Losses Not Affecting Retained Earnings | $319,000 | $55,000 | $14,000 | $0 |
| Other Equity Adjustments | $319,000 | $55,000 | $14,000 | - |
| Retained Earnings | $-101,129,000 | $-163,999,000 | $-233,189,000 | $-281,344,000 |
| Other | ||||
| Treasury Shares Number | $9,028,722 | $8,206,594 | $6,323,892 | $3,235,823 |
| Ordinary Shares Number | $31,707,608 | $31,440,155 | $31,868,549 | $33,848,936 |
| Share Issued | $40,736,330 | $39,646,749 | $38,192,441 | $37,084,759 |
| Tangible Book Value | $-513,760,000 | $-824,893,000 | $-360,134,000 | $-506,321,000 |
| Invested Capital | $1,111,000,000 | $1,081,330,000 | $862,602,000 | $895,793,000 |
| Working Capital | $251,383,000 | $-27,253,000 | $79,685,000 | $-13,737,000 |
| Capital Lease Obligations | $5,539,000 | $6,810,000 | $7,112,000 | $8,224,000 |
| Total Capitalization | $1,082,000,000 | $1,016,747,000 | $679,269,000 | $733,293,000 |
| Treasury Stock | $222,510,000 | $197,505,000 | $137,381,000 | $61,924,000 |
| Additional Paid In Capital | $624,954,000 | $590,251,000 | $565,949,000 | $538,073,000 |
| Capital Stock | $41,000 | $40,000 | $38,000 | $37,000 |
| Common Stock | $41,000 | $40,000 | $38,000 | $37,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $9,111,000 | $10,000,000 | $0 | - |
| Long Term Capital Lease Obligation | $4,132,000 | $5,539,000 | $6,124,000 | $7,112,000 |
| Current Deferred Revenue | $667,000 | $0 | - | - |
| Current Capital Lease Obligation | $1,407,000 | $1,271,000 | $988,000 | $1,112,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $3,714,000 | $4,564,000 | $1,375,000 | $1,507,000 |
| Current Accrued Expenses | $363,552,000 | $387,973,000 | $256,378,000 | $260,761,000 |
| Goodwill | $145,925,000 | $162,333,000 | $133,857,000 | $133,695,000 |
| Net PPE | $16,200,000 | $20,151,000 | $22,012,000 | $26,382,000 |
| Accumulated Depreciation | $-16,542,000 | $-13,534,000 | $-9,678,000 | $-6,323,000 |
| Gross PPE | $32,742,000 | $33,685,000 | $31,690,000 | $32,705,000 |
| Leases | $1,231,000 | $1,231,000 | $1,061,000 | $874,000 |
| Construction In Progress | $1,746,000 | $802,000 | $0 | $0 |
| Other Properties | $25,774,000 | $27,061,000 | $27,108,000 | $28,207,000 |
| Machinery Furniture Equipment | $3,991,000 | $4,591,000 | $3,521,000 | $3,624,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $155,427,000 | $92,198,000 | $71,601,000 | $0 |
| Finished Goods | - | - | $15,208,000 | $16,229,000 |
| Work In Process | - | - | $6,740,000 | $24,672,000 |
| Raw Materials | - | - | $10,384,000 | $5,600,000 |
Fetched: 2026-06-18
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $327,583,000 | $203,328,000 | $274,288,000 | $122,608,000 |
| Operating Activities | ||||
| Operating Cash Flow | $329,323,000 | $204,980,000 | $274,749,000 | $124,230,000 |
| Cash Flow From Continuing Operating Activities | $329,323,000 | $204,980,000 | $274,749,000 | $124,230,000 |
| Operating Gains Losses | $15,994,000 | $11,329,000 | $23,504,000 | - |
| Investing Activities | ||||
| Capital Expenditure | $-1,740,000 | $-1,652,000 | $-461,000 | $-1,622,000 |
| Investing Cash Flow | $-63,532,000 | $-287,759,000 | $-70,812,000 | $-573,691,000 |
| Cash Flow From Continuing Investing Activities | $-63,532,000 | $-287,759,000 | $-70,812,000 | $-573,691,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-25,104,000 | $-60,025,000 | $-75,000,000 | $-14,063,000 |
| Financing Cash Flow | $-110,245,000 | $-60,603,000 | $-140,178,000 | $436,723,000 |
| Cash Flow From Continuing Financing Activities | $-110,245,000 | $-60,603,000 | $-140,178,000 | $436,723,000 |
| Net Other Financing Charges | $-20,401,000 | $-19,170,000 | $-8,361,000 | $-4,044,000 |
| Net Common Stock Issuance | $-25,104,000 | $-60,025,000 | $-75,000,000 | $-14,063,000 |
| Other | ||||
| Repayment Of Debt | $-635,558,000 | $-305,656,000 | $-301,138,000 | $-75,000,000 |
| Issuance Of Debt | $565,175,000 | $313,175,000 | $235,220,000 | $517,682,000 |
| Interest Paid Supplemental Data | $68,760,000 | $62,434,000 | $73,256,000 | $52,528,000 |
| Income Tax Paid Supplemental Data | $60,041,000 | $52,090,000 | $24,205,000 | $10,400,000 |
| End Cash Position | $252,158,000 | $96,612,000 | $239,994,000 | $176,235,000 |
| Beginning Cash Position | $96,612,000 | $239,994,000 | $176,235,000 | $188,973,000 |
| Changes In Cash | $155,546,000 | $-143,382,000 | $63,759,000 | $-12,738,000 |
| Proceeds From Stock Option Exercised | $5,643,000 | $11,073,000 | $9,101,000 | $12,148,000 |
| Common Stock Payments | $-25,104,000 | $-60,025,000 | $-75,000,000 | $-14,063,000 |
| Net Issuance Payments Of Debt | $-70,383,000 | $7,519,000 | $-65,918,000 | $442,682,000 |
| Net Long Term Debt Issuance | $-70,383,000 | $7,519,000 | $-65,918,000 | $442,682,000 |
| Long Term Debt Payments | $-635,558,000 | $-305,656,000 | $-301,138,000 | $-75,000,000 |
| Long Term Debt Issuance | $565,175,000 | $313,175,000 | $235,220,000 | $517,682,000 |
| Net Investment Purchase And Sale | $-61,792,000 | $-18,569,000 | $-70,351,000 | $0 |
| Sale Of Investment | $65,176,000 | $92,602,000 | $22,000,000 | $0 |
| Purchase Of Investment | $-126,968,000 | $-111,171,000 | $-92,351,000 | $0 |
| Net Business Purchase And Sale | $0 | $-267,538,000 | $0 | $-572,069,000 |
| Purchase Of Business | $0 | $-267,538,000 | $0 | $-572,069,000 |
| Net PPE Purchase And Sale | $-1,740,000 | $-1,652,000 | $-461,000 | $-1,622,000 |
| Purchase Of PPE | $-1,740,000 | $-1,652,000 | $-461,000 | $-1,622,000 |
| Change In Working Capital | $3,760,000 | $-54,978,000 | $21,731,000 | $-12,713,000 |
| Change In Other Working Capital | $-197,000 | - | - | $3,000 |
| Change In Payables And Accrued Expense | $74,000 | $-50,421,000 | $2,529,000 | $-34,604,000 |
| Change In Accrued Expense | $-6,644,000 | $-39,143,000 | $-2,532,000 | $-33,897,000 |
| Change In Payable | $6,718,000 | $-11,278,000 | $5,061,000 | $-707,000 |
| Change In Account Payable | $6,718,000 | $-11,278,000 | $5,061,000 | $-707,000 |
| Change In Prepaid Assets | $-7,968,000 | $-14,070,000 | $1,439,000 | $-4,606,000 |
| Change In Inventory | $-5,353,000 | $13,927,000 | $14,169,000 | $48,274,000 |
| Change In Receivables | $17,204,000 | $-4,414,000 | $3,594,000 | $-21,780,000 |
| Changes In Account Receivables | $17,204,000 | $-4,414,000 | $3,594,000 | $-21,780,000 |
| Other Non Cash Items | $5,448,000 | $6,721,000 | $8,355,000 | $8,523,000 |
| Stock Based Compensation | $41,906,000 | $32,400,000 | $27,136,000 | $22,874,000 |
| Amortization Of Securities | $-1,072,000 | $-2,028,000 | $-1,235,000 | $0 |
| Deferred Tax | $-25,657,000 | $-26,814,000 | $-2,153,000 | $-8,391,000 |
| Deferred Income Tax | $-25,657,000 | $-26,814,000 | $-2,153,000 | $-8,391,000 |
| Depreciation Amortization Depletion | $226,074,000 | $169,160,000 | $149,256,000 | $138,939,000 |
| Depreciation And Amortization | $226,074,000 | $169,160,000 | $149,256,000 | $138,939,000 |
| Amortization Cash Flow | $221,892,000 | $165,304,000 | $145,760,000 | $136,255,000 |
| Amortization Of Intangibles | $221,892,000 | $165,304,000 | $145,760,000 | $136,255,000 |
| Depreciation | $4,182,000 | $3,856,000 | $3,496,000 | $2,684,000 |
| Net Income From Continuing Operations | $62,870,000 | $69,190,000 | $48,155,000 | $-25,002,000 |
| Net Intangibles Purchase And Sale | - | - | - | $0 |
| Purchase Of Intangibles | - | - | - | $0 |
| Change In Other Current Liabilities | - | - | - | - |
Fetched: 2026-06-18